Liquid preparation comprising pimobendan
A liquid preparation includes an etherified cyclodextrin derivative and a substituted benzimidazol, where the etherified cyclodextrin derivative is one of alpha-, beta, and gamma-cyclodextrin ether.
1. A liquid preparation comprising an etherified cyclodextrin derivative and pimobendan or a pharmaceutically acceptable salt thereof, wherein the etherified cyclodextrin derivative is selected from the group consisting of alpha-, beta, and gamma-cyclodextrin ether, and wherein the liquid preparation has a pH of 5.5 to 8.5.
2. The liquid preparation according to claim 1 , wherein the etherified cyclodextrin derivative is hydroxypropyl-beta-cyclodextrin.
3. The liquid preparation according to claim 1 , wherein the portion of the etherified cyclodextrin derivative contains about 15 to 40% (w/v).
4. The liquid preparation according to claim 3 , wherein the portion of the etherified cyclodextrin derivative contains about 20 to 30% (w/v).
5. The liquid preparation according to claim 1 , wherein the portion of pimobendan or a pharmaceutical salt thereof contains about 0.005 to 0.15% (w/v).
6. The liquid preparation according to claim 1 , wherein the preparation has pH value of about 6.5 to 7.5 and an osmolality of about 280 to 300 mOsm/Kg.
7. The liquid preparation according to claim 1 , wherein the preparation comprises about:
a) 20 to 30% (w/v) of a hydroxypropyl-beta-cyclodextrin;
b) 0.005 to 0.15% (w/v) pimobendan or a pharmaceutical acceptable salt thereof;
and wherein the pH of the liquid is adjusted to about 6.5 to 7.5 and the osmolality is about 280 to 300 mOsm/Kg.
8. The liquid preparation according to claim 1 , wherein the preparation further comprises pharmaceutical acceptable carriers, excipients, and/or salts.
9. The liquid preparation according to claim 1 , wherein the preparation is isotonic.
10. The liquid preparation according to claim 1 , wherein the preparation contains one or more suitable preservatives.
11. The liquid preparation according to claim 1 , wherein the liquid preparation further comprises 0.025 to 0.075% (w/v) of one or more stabilizers.
12. A kit of parts that comprises:
a) a liquid preparation according to claim 1 ; and
b) a package leaflet including information that the liquid preparation is to be used for the prevention and/or treatment of congestive heart failure in a subject in need of such prevention or treatment.